Protective role of inhaled steroids for COVID-19 infectio

Phase 1

• Conditions: COVID-19; Therapeutic area: Diseases [C] - Virus Diseases [C02]

• Registration Number: EUCTR2020-001306-35-FR
• Lead Sponsor: DRCI APHP

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-03-27
• Last Update Posted: 3 May 2021

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

-Patient = 18 years old
-Laboratory proved infection by COVID-19 within 2 days
-Hospitalization is required (based on investigator judgement)
-Patient affiliated to a social security regime
-Patient able to give free, informed and written consent

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 436
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 436

Exclusion Criteria

-Current treatment with any inhaled steroid
(any other form of steroid administration does not exclude the patient)
-Intensive care unit is required for the patient
(based on investigator judgement)
-Patient with cognitive impairment which do not guarantee proper use of the treatment by the patient himself
-Pregnant or breastfeeding women
-Participation in another interventional drug study involving human participants and concerning COVID-19 infection or being in the exclusion period of a previous study involving human participants
-Contraindications to the treatments
-Not to be resuscitated decision (co-morbidity, …)

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified